NCT06451042Completed
FET-PET/MRI Based Treatment Planning for Glioblastoma Multiforme in Post-Surgical Patients (FET-TREAT)
Source: ClinicalTrials.gov · Last updated 18 Dec 2025
Brief summary (registry, in English)
Glioblastoma multiforme (GBM) represent the most common primary brain malignancy and prognosis remains poor. The most common subtype is glioblastoma which has a 5-year survival rate of approximately 5%. Despite advances in MRI techniques, accurately determining total extent of tumor remains a challenge. The result is incomplete treatment resulting in reduced survival or overtreatment resulting in avoidable treatment related morbidity. A more accurate means of assessing tumor extent is needed to guide management to improve patient survival and quality of life.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 11 (actual)
- First submitted
- 31 May 2024
- Start date
- 1 Jul 2024
- Primary completion date
- 8 Dec 2025
- Lead sponsor
- Sunnybrook Health Sciences Centre
- Diseases
- Glioblastoma
- NCT number
- NCT06451042
What you commit to
- Study type: Observational
- Participants enrolled: 11
- From 1 Jul 2024 to the primary completion date, 8 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Gadolinium allergy
Lab values
- Creatinine clearance \< 30mL/min
Other
- All participants meeting any of the following exclusion criteria at baseline screening will be excluded from participation in this study:
- MRI contraindication
- Inability to lie still for 60 minutes
- Positive pregnancy test
- Breastfeeding
- Patient unable to follow the protocol for any reason
Who the study is looking for
- Each participant must meet all of the following inclusion criteria to participate in this study:
- ≥ 18 years of age
- Diagnosis of glioblastoma multiforme
- Post-maximally safe surgical resection
- No prior radiation or systemic treatment for high grade glioma
- Able to tolerate PET/MRI scan with intravenous contrast
- Willing to provide informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sunnybrook Health Sciences Centre Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.